BAYONNE, N.J., Sept. 16, 2026 (GLOBE NEWSWIRE) — BCB Bancorp, Inc. (the “Company”), (NASDAQ: BCBP), the holding company for BCB Community Bank (the “Bank”), announced today that it has launched an underwritten public offering of shares of its common stock, without par value. In addition, the Company intends to grant the underwriters a 30-day right to purchase additional shares of its common stock.

Piper Sandler & Co. is acting as the sole book-running manager for the proposed offering.

The Company intends to use the net proceeds of this offering of common stock for general corporate purposes, including maintaining liquidity, funding working capital needs, supporting Bank capital including in connection with the expected disposition of identified potential problem loans, reducing debt, and maintaining the Company’s capital and liquidity ratios, and the capital and liquidity ratios of the Bank, at acceptable levels.

Third Quarter Financial Update

The Company also announced today that during the third quarter of 2026, management of the Bank identified for sale and commenced marketing of a portfolio of certain problem loans, most of which are rated criticized or classified under the Bank’s internal risk rating system. The portfolio consists of commercial and multifamily real estate loans with an aggregate unpaid principal balance of approximately $183.4 million, commercial and industrial (C&I) loans with an aggregate unpaid principal balance of approximately $16.7 million, and construction loans with an aggregate unpaid principal balance of approximately $9.8 million, in each case, as of June 30, 2026. Most of these loans have been assigned an internal credit risk rating of either 6 (Special Mention) or 7 (Substandard). None of the Bank’s business express loans are included in the portfolio.

The Bank has received non-binding indications of interest from multiple prospective purchasers covering all of the approximately $210 million aggregate principal balance of the problem loans marketed for sale. Based on those indications, the Bank currently expects to complete the related sales during the third quarter of 2026. Any loans not sold by quarter-end are expected to be transferred to held for sale and recorded at estimated fair value based on prevailing market indications with the sale efforts to continue into the fourth quarter. In addition, during the third quarter the Bank intends to transfer approximately $27 million of commercial real estate loans exhibiting credit weakness to held for sale. The Bank also commenced marketing for the potential sale of its business lines focused on cannabis related customers, including the sale of certain cannabis related loans having an aggregate unpaid principal balance of approximately $69 million and deposits from cannabis related businesses with an aggregate balance of approximately $70 million, in each case as of June 30, 2026. Accordingly, the aggregate of approximately $96 million of commercial real estate loans and the cannabis related loans marketed for sale are expected to be transferred to held for sale in the third quarter of 2026.

The definitive loan purchase agreements for the loan sales are still being negotiated, and the prospective purchasers are continuing to conduct their due diligence reviews of the loans. Accordingly, there can be no assurance that all or any portion of the loans in the marketed portfolio will ultimately be sold, that any such sales will be completed during the third quarter of 2026 or at all, or that the final sales prices will be consistent with the indications of interest received by the Bank. The actual prices at which the loans in the portfolio are sold may be lower than the prices reflected in such indications of interest.

We anticipate our net interest margin for the third quarter to be in the range of 2.90% to 3.00%. We expect to report noninterest income in the range of $5.1 million to $5.7 million and noninterest expense in the range of $17.9 million to $18.5 million. We anticipate that our provision for credit losses for the third quarter will be in the range of $112 million to $120 million, resulting in a substantial net loss for the quarter. Included in loan loss provisioning is an expected $87 million pre-tax loss on the anticipated sale of $210 million of problem loans and the expected transfer to held for sale of an additional $96 million of commercial real estate loans and cannabis related loans. Our anticipated provision for credit losses for the quarter reflects our expectations regarding management’s estimates of the amounts appropriate to maintain adequate balances in our credit loss reserve, in view of recent adjustments to internal risk ratings in our loan portfolio and current market and credit conditions affecting our borrowers.

As a result of the Company’s cumulative loss position in recent years, and anticipated loss at the end of the third quarter of 2026, the Company determined that it is more likely than not that the net deferred tax assets will not be realized and therefore recorded a valuation allowance against its entire net deferred tax asset balance of approximately $50 million for the quarter ended September 30, 2026, which will adversely affect results of operations for the quarter.

As a result of the above items, we currently expect to record a net loss for the third quarter of 2026 in the range of $126.2 million to $136.1 million.

Thomas M. O’Brien, President and Chief Executive Officer of the Company and the Bank, said: “We have spent the last three months reviewing BCB’s legacy credit challenges, re-assessing risk ratings, and developing action plans. When I joined the Company, I stated that my first priority would be to aggressively address these very issues. The actions we are announcing today do just that. While we anticipate a difficult financial result this quarter, I believe that outcome is consistent with our commitment to work through the credit portfolios and put transparent, actionable solutions in place promptly. I believe the totality of the strategic actions announced today lay the foundation for a stronger, sustainable and profitable future.”

Additional Information Regarding the Offering

The offering of common stock is being made pursuant to a registration statement on Form S-3 (File No. 333-298337) that was declared effective by the Securities and Exchange Commission (the “SEC”) on August 25, 2026. A preliminary prospectus supplement to which this communication relates has been filed with the SEC. Prospective investors should read the preliminary prospectus supplement and the accompanying prospectus and other documents the Company has filed with the SEC for more complete information about the Company and the offering. Copies of these documents are available at no charge by visiting the SEC’s website at www.sec.gov. Alternatively, when available, copies of the preliminary prospectus supplement, the prospectus supplement and accompanying prospectus related to the offering may be obtained by contacting Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com.

No Offer or Solicitation

This press release does not constitute an offer to sell, a solicitation of an offer to sell, or the solicitation of an offer to buy any securities. There will be no sale of securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About BCB Bancorp, Inc.

Established in 2000 and headquartered in Bayonne, N.J., BCB Community Bank is the wholly-owned subsidiary of BCB Bancorp, Inc. (NASDAQ: BCBP). The Bank has twenty-two branch offices in Bayonne, Edison, Hoboken, Fairfield, Holmdel, Jersey City, Lyndhurst, Maplewood, Monroe Township, Newark, Plainsboro, River Edge, Rutherford, South Orange, Union, and Woodbridge, New Jersey, and four branches in Hicksville and Staten Island, New York. The Bank provides businesses and individuals a wide range of loans, deposit products, and retail and commercial banking services. For more information, please go to www.bcb.bank.

Forward-Looking Statements

This release, like many written and oral communications presented by BCB Bancorp, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. You can also identify them by the fact that they do not relate strictly to historical or current facts.

Forward-looking statements include statements with respect to our belief, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, including our growth strategy and expansion plans, including potential acquisitions. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements.

Factors that could cause future results to differ materially from those anticipated by our forward-looking statements include the global impact of the United States military conflict with Iran, the periodic Federal budget and funding stalemates in Congress, global tariffs imposed by the Trump administration, higher inflation levels, changes in market interest rates and general economic concerns, all of which could impact our customers’ businesses and the economy and could cause increased loan delinquencies, a reduction in financial transactions and business activities, including decreased deposits and reduced loan originations. Other factors that could cause future results to vary materially from current management expectations as reflected in our forward-looking statements include, but are not limited to: global economic trends and geopolitical risks, including the ongoing conflicts in the Middle East, and changes in the rate of investment or economic growth, including as a result of sanctions, tariffs or other measures; unfavorable economic conditions in the United States generally and particularly in our primary market area and those of our customers, including the periodic Federal budget and funding stalemates in the U.S. Congress; the impact of changes in interest rates and the credit quality and strength of underlying collateral and the effect of such changes on the market value of our loan and investment securities portfolios; the credit risk associated with our loan portfolio; supply chain disruptions and labor shortages; the impact of any future pandemics or other natural disasters; the Company’s ability to effectively attract and deploy deposits; changes in the Company’s corporate strategies, the composition of its assets, or the way in which it funds those assets; the Company’s implementation of anticipated loan sales, which may not be completed in accordance with expected plans or the currently contemplated timeline, or at all, and may be disruptive to the Company and/or reduce the Company’s profitability in future periods; the pending sale of the Company’s cannabis business, which may not be completed in accordance with expected plans or the currently contemplated timeline, or at all, and may be disruptive to the Company and/or reduce the Company’s profitability in future periods; our ability to complete our proposed reincorporation from New Jersey to Delaware, including our ability to receive shareholder approval of the proposed reincorporation, and our ability to realize the anticipated benefits of the proposed reincorporation; shifts in investor sentiment or behavior in the securities, capital, or other financial markets, including changes in market liquidity or volatility; the effects of declines in real estate values that may adversely impact the collateral underlying our loans; increase in unemployment levels and slowdowns in economic growth; changes in the credit performance of our loan portfolio, including levels of criticized and classified loans, nonaccrual loans, and charge-offs; changes in the quality and composition of the Bank’s loan and investment portfolios; deposit flows; changes in liquidity levels, funding sources, or funding costs, and our ability to manage our liquidity risks; legislative and regulatory changes, including but not limited to, increases in Federal Deposit Insurance Corporation (“FDIC”) insurance rates; monetary and fiscal policies of the federal and state governments, including changes in government priorities or budgets; changes in tax policies, rates and regulations of federal, state and local tax authorities; demands for our loan products; demand for financial services; competition; changes in the securities or secondary loan markets; changes in management’s business strategies; our ability to enter new markets successfully; our ability to successfully integrate acquired businesses; changes in consumer spending; our ability to retain key employees; the effects of any reputational, credit, interest rate, market, operational, legal, liquidity, or regulatory risk; potential impact of regulatory requirements, matters, litigation, or other legal actions which could adversely affect operating results; failure to identify and adequately and promptly address cybersecurity risks, including data breaches and cyberattacks; developments in technology, such as artificial intelligence, and our ability to incorporate innovative technologies in our business and provide products and services that satisfy our customers’ expectations for convenience and security; civil unrest in the communities that we serve; changes in accounting principles and guidelines; other economic, competitive, governmental, regulatory, geopolitical and technological factors affecting our operations, pricing and services; and other factors discussed in other reports we filed with the SEC, including under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K filed for the year ended December 31, 2025, as updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and our other periodic reports that we file with the SEC.

CONTACT: JAWAD CHAUDHRY,
  EVP, CFO & TREASURER
  (800) 680-6872
   

MIAMI, FL, Sept. 16, 2026 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC: ETST) (“Earth Science Tech” or the “Company”), operating as a holding company with a diversified highly accountable portfolio of distinct entities, today announced its successful uplisting to the OTCQB Venture Market (the “OTCQB”) effective for trading September 17, 2026.

The OTCQB is a premier, established public market for entrepreneurial and growth-stage companies. To qualify for quotation, companies must meet rigorous financial and reporting standards, undergo an annual verification process, and comply with strict management certification requirements. This ensures elevated transparency and provides investors with a trusted trading environment. Real-time quotes and market information for Earth Science Tech can be found at www.otcmarkets.com, in addition to the Company’s investor relations page.

About Earth Science Tech, Inc. (ETST)

Earth Science Tech, Inc. operates as a diversified holding company focused on the health and wellness sector. The Company’s principal operating strategy is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The Company’s healthcare operations are supported by investments in real estate and asset management activities and a consumer products business.

The core of the Company’s value proposition is the seamless integration of patient care, from consultation to fulfillment. This is achieved through the synergy of specialized subsidiaries.  

To learn more, please visit: www.EarthScienceTech.com 

Forward-Looking Statements

Except for historical information, the matters discussed herein may be considered “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended.

Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including, without limitation, future-oriented statements related to cash flow, gross margins, revenues, and expenses. These statements are based on and reflect our current expectations, estimates, assumptions and/or projections, our perception of historical trends and current conditions, as well as other factors that we believe are appropriate and reasonable under the circumstances. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts. They may include forward-looking words such as “expect,” “expectation,” “believe,” “anticipate,” “may,” “could,” “intend,” “belief,” “plan,” “estimate,” “target,” “predict,” “likely,” “seek,” “project,” “model,” “ongoing,” “will,” “should,” “forecast,” “outlook” or similar terminology. Forward-looking statements are subject to a number of risks and uncertainties that may cause the Company’s actual results to differ materially from our intent, belief or current expectations, including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.

Contact:

Hayden IR
James Carbonara
(646)-755-7412
james@haydenir.com

Brett Maas
(646) 536-7331
brett@haydenir.com

CONSHOHOCKEN, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on September 1, 2026 and September 14, 2026 to a total of 27 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 2,754 shares of Madrigal’s common stock, and in the aggregate 16,149 time-based restricted stock units. All options were granted on September 1, 2026 and have an exercise price of $538.71 per share, which is equal to the closing price of the company’s common stock on the grant date. Options vest as follows: (i) 25% of the option shares will vest on the first anniversary of the grant date and (ii) 6.25% of the option shares will vest on each quarterly anniversary following the first anniversary of the grant date. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

BRISBANE, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on September 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the two new non-executive employees received options to purchase 275,500 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to $3.92, which was the closing price of Annexon’s common stock on September 15, 2026, the date of grant, and vest over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to each employee’s continued service through the applicable vesting dates.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

AerSale Leases Boeing 757-200PCF Freighter to Jupiter Jet

A Boeing 757-200PCF freighter leased by AerSale (NASDAQ: ASLE) to Jupiter Jet, a Kazakhstan-based cargo airline, to support the carrier's expanding regional and international freight operations.
A Boeing 757-200PCF freighter leased by AerSale (NASDAQ: ASLE) to Jupiter Jet, a Kazakhstan-based cargo airline, to support the carrier’s expanding regional and international freight operations.

MIAMI, Sept. 16, 2026 (GLOBE NEWSWIRE) — AerSale Corporation (NASDAQ: ASLE), a leading global supplier of aftermarket commercial aircraft, engines, and proprietary engineered solutions, today announced the lease of a Boeing 757-200PCF aircraft to Jupiter Jet, a Kazakhstan-based cargo airline expanding its regional and international freight operations.

The 757-200PCF offers an ideal combination of payload capability, operating economics and range, making it well suited for express cargo and e-commerce networks throughout Central Asia and neighboring markets. The aircraft will support Jupiter Jet’s continued fleet growth as demand for reliable air cargo capacity continues to increase across the region.

“We are pleased to support Jupiter Jet’s fleet expansion with this Boeing 757 freighter,” said Craig Wright, Senior Vice President & Head of Asset Management. “The 757 remains one of the industry’s most versatile and dependable medium-haul freighters, and this lease demonstrates AerSale’s ability to provide tailored fleet solutions that help operators meet evolving market demand.”

Jupiter Jet has established itself as an emerging cargo operator serving Kazakhstan and surrounding markets, providing flexible freight solutions across Central Asia and beyond. The addition of the Boeing 757 freighter will enhance the airline’s operational capabilities while supporting its long-term growth strategy.

“We are excited to add the Boeing 757 freighter to our fleet through our partnership with AerSale,” said Erik Kozbagarov, Chief Executive Officer of Jupiter Jet. “The aircraft’s performance and economics make it an excellent fit for our expanding cargo network, allowing us to better serve our customers while positioning Jupiter Jet for continued growth.”

AerSale’s aircraft leasing platform provides operators worldwide with flexible fleet solutions backed by the Company’s integrated portfolio of aviation products and services, including aircraft and component maintenance, repair and overhaul (MRO), engine solutions, used serviceable material (USM), and asset management.

About AerSale

AerSale serves airlines operating large jets manufactured by Boeing, Airbus and McDonnell Douglas and is dedicated to providing integrated aftermarket services and products designed to help aircraft owners and operators to realize significant savings in the operation, maintenance and monetization of their aircraft, engines, and components. AerSale’s offerings include Aircraft & Component MRO, Aircraft and Engine Sales and Leasing, Used Serviceable Material sales and internally developed Engineered Solutions to enhance aircraft performance and operating economics (e.g. AerSafe®, AerTrak®, and AerAware™ Enhanced Flight Vision System).

Media:
For more information about AerSale, please visit our website: www.AerSale.com.
Follow us on: LinkedIn | Twitter | Facebook | Instagram

AerSale: Jackie Carlon
Telephone: (305) 764-3200
Email: media.relations@aersale.com

Investor:
AerSale: InvestorRelations@aersale.com

Source: AerSale Corporation

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5b6a14d8-942c-44dd-ae54-84980f05b22a

Shareholders grant the Board discretionary authority to implement a share consolidation of up to 30:1

TORONTO and HAIFA, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, is pleased to announce the voting results from its annual general and special meeting of the shareholders of the Company (“Shareholders”) held on Tuesday, September 15, 2026 (the “Meeting”). Shareholders voted in favour of each resolution put forth at the Meeting.

Annual General and Special Meeting Results

Capitalized terms used but not otherwise defined in this press release have the meanings ascribed to them in the Company’s management information circular dated August 10, 2026 (the “Circular”). Additional information regarding the Consolidation is contained in the Circular and the Company’s press release dated August 21, 2026.

At the Meeting, there were 33 Shareholders represented in person or by proxy holding 32,963,581 Shares, representing 34.90% of the issued and outstanding Shares as at the record date for the Meeting. Each nominee listed in the Circular was reelected as a director of the Company, the results of which were as follows:

Nominee Votes For: Votes Withheld /
Abstained:
Number % Number %
Yoram Drucker 32,187,341 99.96% 12,725 0.04%
Dr. Lior Shaltiel 32,103,881 99.70% 96,185 0.30%
Oded Orgil 30,709,588 95.37% 1,490,478 4.63%
Eyal Gabbai 32,187,566 99.96% 12,500 0.04%
David Stolick 32,178,591 99.93% 21,475 0.07%

In addition, at the Meeting, (i) Shareholders reappointed Ziv Haft, CPA (Isr.), a BDO member firm, as the Company’s auditor for the ensuing year and authorized the Audit Committee of the Board to fix the auditor’s remuneration; (ii) disinterested Shareholders re-approved the Company’s amended and restated omnibus equity incentive plan (the “Plan”); and (iii) Shareholders approved the Consolidation Resolution, each as more particularly set forth in the Circular. The results of such votes were as follows:

Resolution

Votes For: Votes Withheld /
Abstained:
Votes Against:
Number % Number % Number %
Reappointment of Auditor 32,948,451 99.95% 15,130 0.05% N/A N/A
Re-Approval of Amended
and Restated Omnibus
Equity Incentive Plan(1)
24,415,656 99.17% N/A N/A 204,410 0.83%
Approval of the
Consolidation Resolution(2)
32,175,194 97.61% N/A N/A 788,387 2.39%


Notes:

  1. Approved by a majority of the votes cast by disinterested Shareholders. 7,580,000 Shares held by persons ineligible to vote on the Plan resolution were excluded from the vote.
  2. The Consolidation Resolution was approved by not less than 66⅔% of the votes cast by Shareholders at the Meeting.

“We appreciate the support provided by Shareholders for this enabling step in NurExone’s capital-markets strategy,” said Yoram Drucker, Chairman of the Board. “Approval of the Consolidation Resolution provides the Board with flexibility to evaluate market conditions, trading performance and potential U.S. exchange-listing requirements before determining whether, when and at what ratio to implement the Consolidation.”

Shareholder approval authorizes the Board, in its sole discretion, to implement a Consolidation of up to 30 pre-Consolidation Shares for each one post-Consolidation Share at any time within 36 months following approval of the Consolidation Resolution, subject to acceptance of the TSXV and receipt of all other required approvals. Shareholder approval does not require the Board to proceed, and the Board may revoke the Consolidation Resolution or elect not to implement the Consolidation. Any potential U.S. listing would remain subject to further Board approval, acceptance of the TSXV and the applicable U.S. stock exchange, satisfaction of applicable listing standards, regulatory review, market conditions and receipt of all other required approvals.

If implemented by the Board, the exercise prices and numbers of Shares issuable under the Company’s outstanding options, restricted share units, warrants and other securities exercisable, settleable or convertible into Shares will be proportionately adjusted in accordance with their terms.

Shareholders are not required to take any action at this time. If and when the Board determines to implement the Consolidation, further details regarding the timing, final ratio and mechanics will be announced in a subsequent news release. No fractional Shares will be issued in connection with the Consolidation, and any fractional Share that would otherwise result from the Consolidation will be rounded down to the nearest whole Share, as described in the Circular.

Investor Relations Engagement with Acorn Management Partners

The Company has entered into a non-exclusive professional relations and capital markets consulting agreement with Acorn Management Partners, L.L.C. (“Acorn”), an arm’s-length party based in Alpharetta, Georgia. Acorn provides professional-relations and capital markets services focused on increasing a public company’s visibility within the financial professional community. Under the agreement, Acorn will develop and execute a professional-relations program designed to communicate the Company’s publicly disclosed business, financial and corporate developments to licensed brokers, investment professionals and other market participants in the United States. Services may include preparing and distributing educational materials, facilitating discussions and calls with interested financial professionals, providing ongoing feedback regarding market and professional interest, and delivering periodic activity reports to the Company.

Acorn’s approach is focused on professional education and distribution of the Company’s publicly disclosed investment thesis rather than providing investment recommendations, research ratings or price targets. Acorn’s key personnel for the engagement are John Exley III, Chief Executive Officer, and Gregory Lowe, President.

Subject to acceptance by the TSXV, the agreement has a 12-month term ending September 14, 2027, unless terminated earlier in accordance with its terms. The engagement is a cash-only, fee-for-service arrangement, with Acorn to receive monthly cash compensation with a maximum aggregate base fees of US$180000, plus applicable taxes and approved expenses, payable from the Company’s working capital. Acorn will not receive any securities of the Company as compensation. The Company has been advised that neither Acorn nor its key personnel owns or controls any securities of the Company, presently intends to acquire any such securities or participated in a recent financing of the Company. Acorn will not commence providing services until TSXV acceptance has been obtained.

About Acorn
Acorn Management Partners, LLC is a U.S.-based professional-relations and capital markets firm focused on helping public companies build awareness and strengthen relationships within the financial professional community. Acorn works directly with licensed brokers, investment professionals and other market participants to communicate a company’s publicly disclosed investment thesis, business developments and capital markets strategy. Its model combines professional education, financial communications and broker-focused distribution, with experience supporting small- and mid-cap public companies.

About NurExone
NurExone is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitate the Company’s roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top to anchor its North American activity and growth strategy.

For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Russo Partners LLC
Investor and Media Relations – United States
215 Park Ave S, Suite 1905
New York, NY 10003
Phone: 212-845-4200
Email: nurexone@russopartnersllc.com

Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements are often, but not always, identified by words and phrases such as “may”, “will”, “could”, “would”, “expect”, “intend”, “anticipate”, “believe”, “potential”, “proposed”, “subject to”, “position”, “support” and similar expressions.

Forward-looking statements in this press release include, without limitation, statements relating to: whether the Board will implement the Consolidation; the timing and ratio of any Consolidation; the Board’s evaluation of market conditions, trading performance and potential U.S. exchange-listing requirements; receipt of acceptance of the TSXV and other required approvals; the anticipated effects of the Consolidation on the trading price, marketability and liquidity of the Shares; the Company’s evaluation of a potential listing on a major U.S. stock exchange and the anticipated benefits of any such listing; the adjustment of the Company’s outstanding options, restricted share units, warrants and other securities if the Consolidation is implemented; the commencement, term, performance and anticipated activities of the Company’s engagement with Acorn; the expected scope and potential benefits of Acorn’s investor relations and market-awareness services; and statements in the “About NurExone” section regarding the Company’s development plans, regulatory pathway, clinical-trial roadmap, commercialization strategy and platform opportunities.

Forward-looking statements are based on management’s current expectations, beliefs and assumptions as of the date of this press release, including assumptions regarding: the Board’s ability to select and implement an appropriate Consolidation ratio within the authority approved by Shareholders; prevailing market conditions and the trading price of the Shares; receipt of acceptance of the TSXV and other required approvals; the Company’s ability to satisfy applicable listing requirements if it elects to pursue a U.S. exchange listing; Acorn’s ability to perform the services in accordance with the agreement and applicable requirements; the accuracy and continued relevance of the publicly disclosed information used in connection with Acorn’s services; the continued availability of sufficient capital to pay the costs of the Acorn engagement and advance the Company’s activities; the amount of any reimbursable expenses under the Acorn agreement remaining within the Company’s anticipated budget; and the absence of material adverse changes in applicable laws, exchange requirements, market conditions or the Company’s business.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual events or results to differ materially, including, without limitation: the risk that the Board elects not to proceed with the Consolidation or selects a different timing or ratio than anticipated; the risk that required regulatory approvals or acceptance of the TSXV are not obtained; the risk that the Consolidation does not result in a proportionate or sustained increase in the market price of the Shares; the risk that the Consolidation adversely affects trading liquidity or shareholder participation; the risk that the Consolidation does not improve marketability, broaden investor interest or facilitate future financing or capital-markets initiatives; the risk that the Company does not pursue or complete a U.S. exchange listing or satisfy applicable initial or continued listing requirements; the risk that the Acorn engagement does not commence or continue as contemplated; the risk that Acorn’s services do not increase market awareness or result in any anticipated benefit; financing and market risks; regulatory and execution risks; early-stage development risks; the risk that preclinical results are not predictive of clinical outcomes; manufacturing, regulatory, intellectual-property, competition and technological-change risks; and the risks described in the Company’s continuous disclosure filings available under the Company’s SEDAR+ profile at www.sedarplus.ca.

No final decision has been made to implement the Consolidation or pursue any U.S. exchange listing, registration statement, financing or other capital-markets transaction. Any potential U.S. listing would remain subject to further Board approval, applicable Canadian and U.S. regulatory requirements, acceptance of the TSXV and the applicable U.S. stock exchange, satisfaction of all applicable listing standards, market conditions and other customary considerations. There can be no assurance that the Consolidation will be implemented or that any U.S. listing or related capital-markets initiative will be pursued or completed.

Readers are cautioned not to place undue reliance on forward-looking statements. Although the forward-looking statements contained in this press release are based on assumptions that management believes are reasonable as of the date hereof, actual events and results may differ materially. These forward-looking statements are made as of the date of this press release, and the Company undertakes no obligation to update or revise them except as required by applicable law.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) — Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the appointment of Robert (Bob) J. Meyer, MD, a distinguished pulmonary physician and former senior U.S. Food and Drug Administration (“FDA”) leader, to its Board of Directors (the “Board”). Dr. Meyer most recently served as Principal of Drug and Biologics Products at Greenleaf Health, now Eliquent Life Sciences.

“On behalf of the entire Avalyn team, I am thrilled to welcome Bob to our Board of Directors,” said Lyn Baranowski, Chief Executive Officer of Avalyn. “As an accomplished pulmonologist and regulatory leader who spent decades shaping the development and review of respiratory therapies at both the FDA and Merck, Bob brings a rare combination of clinical, scientific, and regulatory expertise. His firsthand experience evaluating therapies at the FDA and advancing products through global development programs gives him a unique perspective on the regulatory, clinical, and strategic considerations that drive successful drug development. His guidance will be invaluable as we advance AP01, AP02, and our emerging combination therapy candidate AP03 through their next stages of clinical development and execution.”

“Avalyn’s inhaled approach represents a compelling opportunity to address the tolerability challenges that limit the use of current antifibrotic therapies and offer new hope to patients living with pulmonary fibrosis,” said Dr. Meyer. “I am honored to join the Board at this pivotal stage for Avalyn. With multiple programs advancing through development, the Company is well positioned to drive meaningful progress for patients with serious respiratory diseases, and I look forward to supporting its vision of transforming the treatment paradigm for these underserved communities.”

Dr. Meyer brings more than 25 years of leadership experience spanning regulatory, academic, and industry roles. He most recently served as a Principal of Drug and Biologics Products at Greenleaf Health, a leading FDA regulatory consulting firm, advising biopharmaceutical companies on regulatory strategy, clinical development and product approvals. Prior to joining Greenleaf, he served as Director of the Virginia Center for Translational and Regulatory Sciences at the University of Virginia School of Medicine.

Before his academic career, Dr. Meyer spent more than 15 years at the FDA, including serving as Director of the Office of Drug Evaluation II within the Center for Drug Evaluation and Research, where he oversaw the review and regulation of pulmonary and allergy, metabolic and endocrine, analgesic and anesthetic, and rheumatologic drug products. Earlier in his FDA tenure, he served as Director of the Division of Pulmonary and Allergy Drug Products, following roles as a medical reviewer and team leader. He subsequently held senior leadership positions at Merck Research Laboratories, including Vice President, Global Regulatory Strategy, Policy and Safety, where he led worldwide regulatory and pharmacovigilance activities. A board-certified pulmonologist and critical care specialist, Dr. Meyer also brings significant public company and governance experience, having served on the boards of multiple biopharmaceutical companies, including Chimerix, Translate Bio, and Correvio.

About Avalyn Pharma
Avalyn aims to transform the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. The company is advancing optimized inhaled formulations of established antifibrotic medicines designed to deliver drug directly to the lungs, enhance local efficacy, and reduce systemic side effects. Avalyn’s AP01 program is an optimized inhaled formulation of pirfenidone currently being evaluated in MIST, a global Phase 2b clinical trial in patients with progressive pulmonary fibrosis (PPF). AP01 has indicated encouraging safety and clinical activity across Phase 1b and multi-year open-label extension trials, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone. Avalyn’s AP02 program is an optimized inhaled formulation of nintedanib currently being evaluated in AURA, a global Phase 2 clinical trial in patients with idiopathic pulmonary fibrosis (IPF). Avalyn is also advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform. By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies. For more information, please visit avalynpharma.com and follow the company on LinkedIn.        

Investor Contact:
Cassie Saitow, Avalyn Pharma Inc.
Sr. Director, IR and Corporate Communications
ir@avalynpharma.com

Media Contact:
Precision AQ
avalyn@precisionaq.com

SPRINGFIELD, Mo., Sept. 16, 2026 (GLOBE NEWSWIRE) — The Board of Directors of Great Southern Bancorp, Inc. (NASDAQ:GSBC), the holding company for Great Southern Bank, declared a $0.43 per common share dividend for the third quarter of the calendar year ending December 31, 2026.

The dividend will be payable on October 14, 2026, to stockholders of record on September 28, 2026. This dividend represents the 147th consecutive quarterly dividend paid by the Company to common stockholders.

About Great Southern Bank

Headquartered in Springfield, Missouri, Great Southern offers a broad range of banking services to customers. The Company operates 87 retail banking centers in Missouri, Iowa, Kansas, Minnesota, and Nebraska and commercial lending offices in Atlanta, Charlotte, Chicago, Dallas, Denver, and Phoenix. The common stock of Great Southern Bancorp, Inc. is listed on the Nasdaq Global Select Market under the symbol “GSBC.”

CONTACT:

Kincade Ayers,
Investor Relations,
(616) 233-0500
GSBC@lambert.com

TORONTO, Sept. 16, 2026 (GLOBE NEWSWIRE) — (TSX: PFIA, PFCO, PFCB, PFAA, PFIG) Picton Mahoney Asset Management (“PICTON Investments”) announced today that it has declared the September 2026 monthly cash distribution of $0.0481 per unit for the ETF units (“ETF Units”) of the PICTON Long Short Income Alternative Fund.

PICTON Investments announced today that it has declared the September 2026 monthly cash distribution of $0.0403 per unit for the ETF Units of the PICTON Credit Opportunities Alternative Fund.

PICTON Investments announced today that it has declared the September 2026 monthly cash distribution of $0.0320 per unit for the ETF Units of the PICTON Core Bond Fund.

PICTON Investments announced today that it has declared the September 2026 monthly cash distribution of $0.0404 per unit for the ETF Units of the PICTON Multi-Strategy Alpha Alternative Fund.

PICTON Investments announced today that it has declared the September 2026 monthly cash distribution of $0.0644 per unit for the ETF units of the PICTON Investment Grade Alternative Fund.

Unitholders of record of the ETF Units, at the close of business on September 22, 2026, will receive a per-unit cash distribution payable on September 30, 2026.

About PICTON Investments

PICTON Investments is a Canadian investment firm with $20.0 billion in assets under management (as at August 31, 2026), recognized for pioneering alternative investment strategies that challenge traditional thinking. Since 2004, we have been helping advisors and investors rethink portfolio construction – moving away from traditional models toward more resilient, diversified solutions. Leveraging deep expertise in quantitative research, fundamental analysis, and authentic hedging strategies, we champion a modern approach designed to deliver more consistent, risk-adjusted returns. Our philosophy is to “Build from the Bear Up,” embracing a bear mindset of resiliency, adaptability, and strength to provide Canadians with greater certainty.

For further information please contact:

Arthur Galloway
Picton Mahoney Asset Management
Tel: (416) 955-4108
Website: www.pictoninvestments.com
Email: invest@pictoninvestments.com

FORT COLLINS, Colo., Sept. 16, 2026 (GLOBE NEWSWIRE) — Woodward, Inc. (NASDAQ:WWD) today announced that its Board of Directors declared a cash dividend of $0.32 per share for the quarter, payable on December 3, 2026, for stockholders of record as of November 19, 2026.

About Woodward, Inc.

Woodward is the global leader in the design, manufacture, and service of energy conversion and control solutions for the aerospace and industrial equipment markets. Our purpose is to design and deliver energy control solutions our partners count on to power a clean future. Our innovative fluid, combustion, electrical, propulsion and motion control systems perform in some of the world’s harshest environments. Woodward is a global company headquartered in Fort Collins, Colorado, USA. Visit our website at www.woodward.com.

Notice Regarding Forward-Looking Statements

The statements in this release contain forward-looking statements that involve risks and uncertainties, including statements concerning the company’s cash dividend. Actual results could differ materially from projections or any other forward-looking statements and we have no obligation to update our forward-looking statements except as required by law. Factors that could affect performance and could cause actual results to differ materially from projections and forward-looking statements are described in Woodward’s Annual Report and Form 10-K for the year ended September 30, 2025, and any subsequently filed Quarterly Report on Form 10-Q.

CONTACT:
Dan Provaznik
Director Investor Relations
970-498-3849
Dan.Provaznik@Woodward.com 

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.